Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.38
ALXN's Cash-to-Debt is ranked lower than
90% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ALXN: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
ALXN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 2.69 Max: 375
Current: 0.38
0.31
375
Equity-to-Asset 0.65
ALXN's Equity-to-Asset is ranked lower than
54% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALXN: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
ALXN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.66 Max: 0.95
Current: 0.65
0.04
0.95
Debt-to-Equity 0.35
ALXN's Debt-to-Equity is ranked lower than
58% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. ALXN: 0.35 )
Ranked among companies with meaningful Debt-to-Equity only.
ALXN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.35 Max: 17.46
Current: 0.35
0
17.46
Debt-to-EBITDA 4.53
ALXN's Debt-to-EBITDA is ranked lower than
77% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. ALXN: 4.53 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALXN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03  Med: 0.53 Max: 5.05
Current: 4.53
0.03
5.05
Interest Coverage 10.30
ALXN's Interest Coverage is ranked lower than
85% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 10.30 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 8.17  Med: 99.52 Max: 310.04
Current: 10.3
8.17
310.04
Piotroski F-Score: 5
Altman Z-Score: 4.31
Beneish M-Score: -2.20
WACC vs ROIC
7.83%
-12.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.36
ALXN's Operating Margin % is ranked higher than
92% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ALXN: 27.36 )
Ranked among companies with meaningful Operating Margin % only.
ALXN' s Operating Margin % Range Over the Past 10 Years
Min: 13.36  Med: 27.09 Max: 41
Current: 27.36
13.36
41
Net Margin % -2.67
ALXN's Net Margin % is ranked higher than
71% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ALXN: -2.67 )
Ranked among companies with meaningful Net Margin % only.
ALXN' s Net Margin % Range Over the Past 10 Years
Min: -2.67  Med: 17.12 Max: 76.31
Current: -2.67
-2.67
76.31
ROE % -1.12
ALXN's ROE % is ranked higher than
76% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ALXN: -1.12 )
Ranked among companies with meaningful ROE % only.
ALXN' s ROE % Range Over the Past 10 Years
Min: -1.12  Med: 14.48 Max: 63.11
Current: -1.12
-1.12
63.11
ROA % -0.73
ALXN's ROA % is ranked higher than
78% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ALXN: -0.73 )
Ranked among companies with meaningful ROA % only.
ALXN' s ROA % Range Over the Past 10 Years
Min: -0.73  Med: 9.66 Max: 46.71
Current: -0.73
-0.73
46.71
ROC (Joel Greenblatt) % 8.62
ALXN's ROC (Joel Greenblatt) % is ranked higher than
82% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ALXN: 8.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALXN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.62  Med: 54.13 Max: 173.84
Current: 8.62
8.62
173.84
3-Year Revenue Growth Rate 12.50
ALXN's 3-Year Revenue Growth Rate is ranked higher than
69% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALXN: 12.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALXN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 28.3 Max: 462.4
Current: 12.5
0
462.4
3-Year EBITDA Growth Rate 3.60
ALXN's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ALXN: 3.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALXN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.2 Max: 73.2
Current: 3.6
0
73.2
3-Year EPS without NRI Growth Rate -15.50
ALXN's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ALXN: -15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALXN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.7 Max: 67.1
Current: -15.5
0
67.1
GuruFocus has detected 2 Warning Signs with Alexion Pharmaceuticals Inc ALXN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALXN's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ALXN Guru Trades in Q3 2017

George Soros 4,800 sh (New)
Ray Dalio 117,418 sh (+1735.23%)
Jim Simons 442,200 sh (+108.29%)
Paul Tudor Jones 13,425 sh (+86.28%)
Pioneer Investments 77,110 sh (+47.64%)
Joel Greenblatt 32,126 sh (+10.70%)
David Carlson 430,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 143,788 sh (unchged)
John Paulson Sold Out
Daniel Loeb 1,000,000 sh (-20.00%)
Frank Sands 4,775,947 sh (-24.74%)
Steven Cohen 59,900 sh (-85.83%)
» More
Q4 2017

ALXN Guru Trades in Q4 2017

Pioneer Investments 1,454,498 sh (+1786.26%)
Steven Cohen 222,737 sh (+271.85%)
Mario Gabelli 6,000 sh (+50.00%)
David Carlson 450,000 sh (+4.65%)
Daniel Loeb Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Frank Sands 4,553,095 sh (-4.67%)
Ray Dalio 65,212 sh (-44.46%)
Jim Simons 178,800 sh (-59.57%)
Paul Tudor Jones 2,264 sh (-83.14%)
Eaton Vance Worldwide Health Sciences Fund 133,485 sh (-7.17%)
» More
Q1 2018

ALXN Guru Trades in Q1 2018

Paul Tudor Jones 20,202 sh (+792.31%)
David Carlson 530,000 sh (+17.78%)
Mario Gabelli 6,000 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Frank Sands 3,441,608 sh (-24.41%)
Pioneer Investments 977,301 sh (-32.81%)
Steven Cohen 85,000 sh (-61.84%)
Eaton Vance Worldwide Health Sciences Fund 124,300 sh (-6.88%)
» More
Q2 2018

ALXN Guru Trades in Q2 2018

First Eagle Investment 214,982 sh (New)
Ray Dalio 17,053 sh (New)
Steven Cohen 437,800 sh (+415.06%)
Paul Tudor Jones 37,743 sh (+86.83%)
David Carlson 570,000 sh (+7.55%)
Eaton Vance Worldwide Health Sciences Fund 130,059 sh (+4.63%)
Frank Sands 3,224,339 sh (-6.31%)
Mario Gabelli 5,000 sh (-16.67%)
Pioneer Investments 497,728 sh (-49.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-06-30 New Buy0.07%$106.04 - $127.57 $ 128.9010%214,982
Mario Gabelli 2018-06-30 Reduce -16.67%$106.04 - $127.57 $ 128.9010%5,000
Mario Gabelli 2017-12-31 Add 50.00%$106.78 - $143.84 $ 128.906%6,000
George Soros 2017-12-31 Sold Out 0.02%$106.78 - $143.84 $ 128.906%0
Joel Greenblatt 2017-12-31 Sold Out 0.07%$106.78 - $143.84 $ 128.906%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541714    SIC: 8731
Compare:XKRX:207940, XKRX:068270, NAS:REGN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:VRTX, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY, NAS:BGNE, NAS:JAZZ, NAS:BLUE, NAS:SGEN » details
Traded in other countries:ALXN.Austria, AXP.Germany, ALXN.Mexico, ALXN.Switzerland, 0QZM.UK,
Headquarter Location:USA
Alexion Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Guru Investment Theses on Alexion Pharmaceuticals Inc

Spiros Segalas Commentary on Alexion Pharmaceuticals - Jul 10, 2017

In Health Care, Alexion Pharmaceuticals’ (NASDAQ:ALXN) weakness reflected investor concern about a change in senior management and disappointment that the Food and Drug Administration did not grant priority review for the company’s drug Soliris as a treatment for an ultra-rare form of myasthenia gravis. Soliris is already approved to treat two rare, genetic, and potentially life-threatening blood disorders. Other approved drugs target a disease caused by genetic mutations and an ultra-rare metabolic disorder.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Ratios

vs
industry
vs
history
Forward PE Ratio 15.29
ALXN's Forward PE Ratio is ranked higher than
69% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. ALXN: 15.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.28
ALXN's PB Ratio is ranked higher than
61% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALXN: 3.28 )
Ranked among companies with meaningful PB Ratio only.
ALXN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.27 Max: 28.51
Current: 3.28
2.47
28.51
PS Ratio 7.70
ALXN's PS Ratio is ranked higher than
63% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 7.70 )
Ranked among companies with meaningful PS Ratio only.
ALXN' s PS Ratio Range Over the Past 10 Years
Min: 6.7  Med: 14.36 Max: 38.88
Current: 7.7
6.7
38.88
Price-to-Free-Cash-Flow 170.96
ALXN's Price-to-Free-Cash-Flow is ranked lower than
85% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. ALXN: 170.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALXN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.23  Med: 60.19 Max: 4990
Current: 170.96
25.23
4990
Price-to-Operating-Cash-Flow 60.06
ALXN's Price-to-Operating-Cash-Flow is ranked lower than
71% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. ALXN: 60.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALXN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 18.13  Med: 47.15 Max: 83.95
Current: 60.06
18.13
83.95
EV-to-EBIT 168.29
ALXN's EV-to-EBIT is ranked lower than
92% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ALXN: 168.29 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -98.6  Med: 48.45 Max: 893.9
Current: 168.29
-98.6
893.9
EV-to-EBITDA 44.77
ALXN's EV-to-EBITDA is ranked lower than
77% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ALXN: 44.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -119  Med: 42.6 Max: 334.6
Current: 44.77
-119
334.6
EV-to-Revenue 8.10
ALXN's EV-to-Revenue is ranked higher than
63% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ALXN: 8.10 )
Ranked among companies with meaningful EV-to-Revenue only.
ALXN' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.1  Med: 14.5 Max: 40.7
Current: 8.1
7.1
40.7
Shiller PE Ratio 93.76
ALXN's Shiller PE Ratio is ranked lower than
74% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. ALXN: 93.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALXN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 68.65  Med: 178.76 Max: 1466
Current: 93.76
68.65
1466
Current Ratio 2.72
ALXN's Current Ratio is ranked lower than
66% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ALXN: 2.72 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.54 Max: 52.92
Current: 2.72
1.38
52.92
Quick Ratio 2.27
ALXN's Quick Ratio is ranked lower than
68% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ALXN: 2.27 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.17 Max: 52.92
Current: 2.27
1.38
52.92
Days Inventory 333.68
ALXN's Days Inventory is ranked lower than
86% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. ALXN: 333.68 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 350.37 Max: 532.25
Current: 333.68
202.61
532.25
Days Sales Outstanding 83.20
ALXN's Days Sales Outstanding is ranked lower than
64% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ALXN: 83.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.73  Med: 97.18 Max: 113.85
Current: 83.2
70.73
113.85
Days Payable 43.97
ALXN's Days Payable is ranked lower than
63% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ALXN: 43.97 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 43.97  Med: 90.68 Max: 111.37
Current: 43.97
43.97
111.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.70
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ALXN: -3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -7.8 Max: -2.4
Current: -3.7
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.01
ALXN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. ALXN: 2.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALXN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.58  Med: 5.19 Max: 142.22
Current: 2.01
1.58
142.22
Price-to-Median-PS-Value 0.54
ALXN's Price-to-Median-PS-Value is ranked higher than
79% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ALXN: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALXN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.28 Max: 59.41
Current: 0.54
0.43
59.41
Earnings Yield (Greenblatt) % 0.59
ALXN's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ALXN: 0.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALXN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.3  Med: 2 Max: 3.1
Current: 0.59
-4.3
3.1
Forward Rate of Return (Yacktman) % 12.41
ALXN's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. ALXN: 12.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALXN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.5  Med: 1 Max: 22.5
Current: 12.41
-18.5
22.5

More Statistics

Revenue (TTM) (Mil) $3,745.00
EPS (TTM) $ -0.45
Beta0.88
Volatility29.07%
52-Week Range $102.10 - 144.91
Shares Outstanding (Mil)222.86

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 4,081 4,854 5,728 6,777
EBIT (Mil $) 512 1,724 2,123
EBITDA (Mil $) 976 2,188 2,549
EPS ($) 1.43 6.10 7.89 12.68
EPS without NRI ($) 1.43 6.10 7.89 12.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.68%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}